Medelis Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Nashville TN United States (1973)
Status: Acquired by WCCT Global (2016) → now Novo Nordisk (2021)

Organization Overview

First Clinical Trial
2016
NCT02464007
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (2)

becaplermin (regranex) (1 trial)

pacritinib (Vonjo) (1 trial)

Drugs in Phase 1 Trials (2)

rsifn-co (1 trial)

tld1433 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Foot (Phase 2)

Foot Ulcer (Phase 2)

Lung Neoplasms (Phase 2)

Neuroendocrine Tumors (Phase 1)

Ulcer (Phase 2)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4